- MyoKardia (NASDAQ:MYOK) offered 5,437,500 shares of common stock at $10 per share. Underwriters over-allotment is an additional 815,625 shares. Closing date is November 3.
- The original IPO was 4,687,500 shares at $15 - 17.
- Previously: MyoKardia set for IPO (Oct. 22)
- MyoKardia offers a valuable solution in a distinct market but the company is only in Phase 1 of testing its first therapies.
- MyoKardia predicted bringing home $91.6 million with its IPO. The company’s take home was only $54 million.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
Address
333 Allerton Ave
SOUTH SAN FRANCISCO, CA 94080-4816
United States
SOUTH SAN FRANCISCO, CA 94080-4816
United States
Website
http://www.myokardia.comKey stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -228.21% | -33.55% |
| Operating margin | -233.71% | -33.94% |
| EBITD margin | - | -31.11% |
| Return on average assets | -29.08% | -8.27% |
| Return on average equity | -39.69% | -10.99% |
| Employees | 78 |
No comments:
Post a Comment